199 related articles for article (PubMed ID: 35037771)
1. Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.
Bardaro F; Stirpe E
J Oncol Pharm Pract; 2022 Jun; 28(4):989-994. PubMed ID: 35037771
[TBL] [Abstract][Full Text] [Related]
2. Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.
Schiefer M; Hendriks LEL; Dinh T; Lalji U; Dingemans AC
Eur J Cancer; 2018 Mar; 91():92-98. PubMed ID: 29413968
[TBL] [Abstract][Full Text] [Related]
3. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
4. Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC).
Watanabe H; Ichihara E; Kano H; Ninomiya K; Tanimoto M; Kiura K
Intern Med; 2017 Aug; 56(16):2195-2197. PubMed ID: 28781309
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.
Bollinger MK; Agnew AS; Mascara GP
J Oncol Pharm Pract; 2018 Jul; 24(5):379-388. PubMed ID: 28565936
[TBL] [Abstract][Full Text] [Related]
7. [A Case of Significant Ejection Fraction Reduction and Heart Failure Induced by Osimertinib].
Ito S; Otsuka A; Ishii H; Nishihira R; Hirai Y; Nagasawa R; Inoue R; Chin K; Kaneko T
Gan To Kagaku Ryoho; 2020 Apr; 47(4):609-613. PubMed ID: 32389962
[TBL] [Abstract][Full Text] [Related]
8. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the
Furuta H; Uemura T; Yoshida T; Kobara M; Yamaguchi T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Sakao Y; Yatabe Y; Hida T
Anticancer Res; 2018 Sep; 38(9):5231-5237. PubMed ID: 30194172
[TBL] [Abstract][Full Text] [Related]
10. Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation-A Case Report and a Review of the Literature.
Sato I; Mizuno H; Kataoka N; Kunimatsu Y; Tachibana Y; Sugimoto T; Tani N; Ogura Y; Hirose K; Takeda T
Medicina (Kaunas); 2020 Aug; 56(8):. PubMed ID: 32796633
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
12. Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review.
Zhang Q; Liu H; Yang J
Front Endocrinol (Lausanne); 2022; 13():833929. PubMed ID: 35677717
[TBL] [Abstract][Full Text] [Related]
13. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
[TBL] [Abstract][Full Text] [Related]
14. Overall Survival with Osimertinib in Untreated,
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
[TBL] [Abstract][Full Text] [Related]
15. Osimertinib induced cardiomyopathy: A case report.
Shinomiya S; Kaira K; Yamaguchi O; Ishikawa K; Kagamu H
Medicine (Baltimore); 2020 Sep; 99(39):e22301. PubMed ID: 32991436
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS).
Anand K; Ensor J; Trachtenberg B; Bernicker EH
JACC CardioOncol; 2019 Dec; 1(2):172-178. PubMed ID: 34396179
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
[TBL] [Abstract][Full Text] [Related]
20. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
